One intangible into the model is that over the next 2-3 years there will be some attrition on the part of medical centers who currently do their own genotyping for specific / limited targets. I think that cost cutting / outsourcing efforts at these centers will begin, sending more work to FMI.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.